



Supplementary Figure S1



Supplementary figure S1. Box and whisker plots of retention parameters at the day of HSCT and 1 year later.

Absolute values of cystatin C at the day of HSCT (n=57) and 1 year later (n=42) **(A)**. Cystatin C and Creatinine relative to baseline at HSCT one year after HSCT **(B)**. Medians are depicted in red. HSCT= hematopoetic stem cell transplantation; n.s.= not significant calculated with Wilcoxon matched-pairs signed rank test.

Supplementary Figure S2



Supplementary figure S2. Distribution of acute graft-versus-host disease grades.

Different grades of acute graft-versus-host disease are depicted irrespective of their onset in both the everolimus and the ciclosporin A group as a percentage of total patients per group.

Supplementary table S1. Adverse events related to endothelial damage

	Number of cases	Incidence (%)	Number of cases with onset before switch to everolimus
Sinusoidal obstruction syndrome (SOS)	12	21.1	8
Transplant-associated thrombotic microangiopathy (TA-TMA)	2	3.5	0